FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898091943> ?p ?o ?g. }

• W2898091943 abstract "Neurofibrillary pathology composed of tau protein is closely correlated with severity and phenotype of cognitive impairment in patients with Alzheimer’s disease and non-Alzheimer’s tauopathies. Targeting pathological tau proteins via immunotherapy is a promising strategy for disease-modifying treatment of Alzheimer’s disease. Previously, we reported a 24-week phase 1 trial on the active vaccine AADvac1 against pathological tau protein; here, we present the results of a further 72 weeks of follow-up on those patients. We did a phase 1, 72-week, open-label study of AADvac1 in patients with mild to moderate Alzheimer’s disease who had completed the preceding phase 1 study. Patients who were previously treated with six doses of AADvac1 at monthly intervals received two booster doses at 24-week intervals. Patients who were previously treated with only three doses received another three doses at monthly intervals, and subsequently two boosters at 24-week intervals. The primary objective was the assessment of long-term safety of AADvac1 treatment. Secondary objectives included assessment of antibody titres, antibody isotype profile, capacity of the antibodies to bind to AD tau and AADvac1, development of titres of AADvac1-induced antibodies over time, and effect of booster doses; cognitive assessment via 11-item Alzheimer’s Disease Assessment Scale cognitive assessment (ADAS-Cog), Category Fluency Test and Controlled Oral Word Association Test; assessment of brain atrophy via magnetic resonance imaging (MRI) volumetry; and assessment of lymphocyte populations via flow cytometry. The study was conducted between 18 March 2014 and 10 August 2016. Twenty-six patients who completed the previous study were enrolled. Five patients withdrew because of adverse events. One patient was withdrawn owing to noncompliance. The most common adverse events were injection site reactions (reported in 13 [50%] of vaccinated patients). No cases of meningoencephalitis or vasogenic oedema were observed. New micro-haemorrhages were observed only in one ApoE4 homozygote. All responders retained an immunoglobulin G (IgG) antibody response against the tau peptide component of AADvac1 over 6 months without administration, with titres regressing to a median 15.8% of titres attained after the initial six-dose vaccination regimen. Booster doses restored previous IgG levels. Hippocampal atrophy rate was lower in patients with high IgG levels; a similar relationship was observed in cognitive assessment. AADvac1 displayed a benign safety profile. The evolution of IgG titres over vaccination-free periods warrants a more frequent booster dose regimen. The tendency towards slower atrophy in MRI evaluation and less of a decline in cognitive assessment in patients with high titres is encouraging. Further trials are required to expand the safety database and to establish proof of clinical efficacy of AADvac1. The studies are registered with the EU Clinical Trials Register and ClinicalTrials.gov : the preceding first-in-human study under EudraCT 2012-003916-29 and NCT01850238 (registered on 9 May 2013) and the follow-up study under EudraCT 2013-004499-36 and NCT02031198 (registered 9 Jan 2014), respectively." @default.
• W2898091943 created "2018-11-02" @default.
• W2898091943 creator A5001052793 @default.
• W2898091943 creator A5004900030 @default.
• W2898091943 creator A5008024977 @default.
• W2898091943 creator A5013336796 @default.
• W2898091943 creator A5017902933 @default.
• W2898091943 creator A5025878691 @default.
• W2898091943 creator A5028810504 @default.
• W2898091943 creator A5032340198 @default.
• W2898091943 creator A5033296355 @default.
• W2898091943 creator A5036858038 @default.
• W2898091943 creator A5036911759 @default.
• W2898091943 creator A5037074908 @default.
• W2898091943 creator A5044567919 @default.
• W2898091943 creator A5056611047 @default.
• W2898091943 creator A5060534520 @default.
• W2898091943 creator A5066195949 @default.
• W2898091943 creator A5073021016 @default.
• W2898091943 creator A5080958609 @default.
• W2898091943 creator A5081283156 @default.
• W2898091943 creator A5088031089 @default.
• W2898091943 date "2018-10-24" @default.
• W2898091943 modified "2023-10-02" @default.
• W2898091943 title "FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease" @default.
• W2898091943 cites W1966879670 @default.
• W2898091943 cites W1975657945 @default.
• W2898091943 cites W1994397669 @default.
• W2898091943 cites W2006096283 @default.
• W2898091943 cites W2028942474 @default.
• W2898091943 cites W2036755018 @default.
• W2898091943 cites W2038003980 @default.
• W2898091943 cites W2044321001 @default.
• W2898091943 cites W2052742260 @default.
• W2898091943 cites W2053230968 @default.
• W2898091943 cites W2053488262 @default.
• W2898091943 cites W2061471972 @default.
• W2898091943 cites W2063808031 @default.
• W2898091943 cites W2074259682 @default.
• W2898091943 cites W2074274706 @default.
• W2898091943 cites W2080274663 @default.
• W2898091943 cites W2084009738 @default.
• W2898091943 cites W2090968981 @default.
• W2898091943 cites W2093092963 @default.
• W2898091943 cites W2096947785 @default.
• W2898091943 cites W2102389579 @default.
• W2898091943 cites W2103481737 @default.
• W2898091943 cites W2112579276 @default.
• W2898091943 cites W2115017507 @default.
• W2898091943 cites W2118101413 @default.
• W2898091943 cites W2127117802 @default.
• W2898091943 cites W2133881478 @default.
• W2898091943 cites W2136995208 @default.
• W2898091943 cites W2137140827 @default.
• W2898091943 cites W2137176838 @default.
• W2898091943 cites W2139886607 @default.
• W2898091943 cites W2144356782 @default.
• W2898091943 cites W2145440751 @default.
• W2898091943 cites W2147317695 @default.
• W2898091943 cites W2157064933 @default.
• W2898091943 cites W2158118162 @default.
• W2898091943 cites W2185034389 @default.
• W2898091943 cites W2189621653 @default.
• W2898091943 cites W2192012340 @default.
• W2898091943 cites W2340839875 @default.
• W2898091943 cites W2508663370 @default.
• W2898091943 cites W2559946394 @default.
• W2898091943 cites W2565340265 @default.
• W2898091943 cites W2572208524 @default.
• W2898091943 cites W2617072792 @default.
• W2898091943 cites W2695553179 @default.
• W2898091943 cites W2727929522 @default.
• W2898091943 cites W2736509962 @default.
• W2898091943 cites W2789516300 @default.
• W2898091943 cites W2793147351 @default.
• W2898091943 doi "https://doi.org/10.1186/s13195-018-0436-1" @default.
• W2898091943 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6201586" @default.
• W2898091943 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30355322" @default.
• W2898091943 hasPublicationYear "2018" @default.
• W2898091943 type Work @default.
• W2898091943 sameAs 2898091943 @default.
• W2898091943 citedByCount "79" @default.
• W2898091943 countsByYear W28980919432018 @default.
• W2898091943 countsByYear W28980919432019 @default.
• W2898091943 countsByYear W28980919432020 @default.
• W2898091943 countsByYear W28980919432021 @default.
• W2898091943 countsByYear W28980919432022 @default.
• W2898091943 countsByYear W28980919432023 @default.
• W2898091943 crossrefType "journal-article" @default.
• W2898091943 hasAuthorship W2898091943A5001052793 @default.
• W2898091943 hasAuthorship W2898091943A5004900030 @default.
• W2898091943 hasAuthorship W2898091943A5008024977 @default.
• W2898091943 hasAuthorship W2898091943A5013336796 @default.
• W2898091943 hasAuthorship W2898091943A5017902933 @default.
• W2898091943 hasAuthorship W2898091943A5025878691 @default.
• W2898091943 hasAuthorship W2898091943A5028810504 @default.
• W2898091943 hasAuthorship W2898091943A5032340198 @default.
• W2898091943 hasAuthorship W2898091943A5033296355 @default.
• W2898091943 hasAuthorship W2898091943A5036858038 @default.
• W2898091943 hasAuthorship W2898091943A5036911759 @default.

• next